A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas

Inclusion Criteria:

- Have measurable lesions

- Have recovered from prior chemotherapies

- Have an estimated life expectancy of at least 12 weeks

- Hepatic: total bilirubin less than or equal to 1.5 XULN; ATL/AST less than or equal
to 2.0 x ULN (less than 5x if liver metastases are present)

- Renal: serum creatinine less than or equal to 1.5XULN

- Adequate bone marrow reserve: platelets greater than or equal to 75 x 109 /L,
absolute neutrophil count (ANC) greater than or equal to 1.0 x 09 /L

Exclusion Criteria:

- Have a second primary malignancy (except adequately treated nonmelanomatous skin
cancer, or other cancer that is considered cured by surgical resection or radiation).

- Anti-lymphoma therapy within the past 3 weeks

- Unable to swallow tablets

- Unable to discontinue use of carbamazepine, phenobarbital and phenytoin at least 14
days prior to study enrollment